http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2724714-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95a2f6cf8f7faa2e9c94695d49f23ee9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-14 |
| filingDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cbd7922a59ab5e2a60ba8c80b10224a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83f0b0eb5a574c7f35d8fcb234c3b577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0480fd184f94bab61744e0251eb2f20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_322eaf6322bf4fda7460bea2b09a8c0d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_773b95a31217f07b43be3027fbc6f095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f1629a0afb5d53a08735caac8741722 |
| publicationDate | 2020-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2724714-C1 |
| titleOfInvention | Method for conjugation of human heavy chain constant fragment and peptoid analogue of autoantigen mog35-55 for multiple sclerosis therapy |
| abstract | FIELD: biotechnology. n SUBSTANCE: invention relates to biotechnology, specifically to a method for conjugating a recombinant constant fragment of a human immunoglobulin heavy chain (Fc) and a peptoid analogue of autoantigen MOG35-55 (AMogP3). Chemical conjugation of Fc with a bifunctional cross-linker linker NHS-PEG2-maleimide is carried out at a ratio of reagents of 1:10 and an optimum length of the cross-linking reagent of 17.6 angstroms. Obtained fragment Fc-linker is purified from unreacted linker by means of desalting chromatographic column. Chemical conjugation of peptide AMogP3 carrying a free thiol group and a Fc-linker fragment are carried out at the ratio of reagents Fc-linker: peptoid = 1:2. Fc-linker: peptoid mixture is concentrated with cooling to 4 °C. Obtained bifunctional agent Fc-linker-peptoid module AMogP3 is purified from unreacted peptoid AMogP3 by gel filtration chromatography. Duration of one complete cycle of extraction and purification is 3 hours. Output of target product is 61.2 %. Invention improves efficiency of conjugation of peptoid analogue of autoantigen MOG35-55 with a constant domain of a heavy chain of human immunoglobulin. n EFFECT: prepared conjugate is suitable for multiple sclerosis therapy. n 1 cl, 4 dwg, 1 tbl, 4 ex |
| priorityDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.